Latest Leadership Changes News

Strike Energy shakes up leadership with Shelley Robertson stepping in as CEO and a leaner board under new chair Nev Power, signaling a strategic pivot amid ongoing project development.

Lodestar Minerals has identified five new copper-molybdenum-gold porphyry targets at Los Loros, Chile, and confirmed encouraging IOCG-style alteration at Three Saints, setting the stage for maiden drilling campaigns.

CSL Limited’s interim CEO Gordon Naylor reveals a downgraded FY26 outlook amid slower growth and announces substantial impairments tied to CSL Vifor assets. Leadership changes and transformation efforts aim to restore momentum.

Lithium Plus Minerals has announced the immediate resignation of CEO Andrew Haythorpe for personal reasons, with Chair Bin Guo stepping in as acting CEO. This leadership shift comes amid ongoing development at the company’s Northern Territory lithium projects.

Fluence Corporation Limited (ASX: FLC) reports a 52% revenue surge in FY2025 driven by strategic growth in Smart Product Solutions and recurring revenue, alongside progress on a major Ivory Coast water treatment plant.

Spenda Limited has sold its Ledger platform to APG Pay for $1.8 million, cutting $2.7 million in annual costs and streamlining operations to concentrate on its core revenue-generating products.

CZR Resources shakes up leadership with Managing Director Stefan Murphy's exit and Milan Jerkovic stepping in as Acting CEO, accompanied by the appointment of Alex Neuling as an independent director.

Schoolblazer reports a modest revenue dip to $55.4m in 1H FY26 amid supply chain and geopolitical headwinds but strengthens its balance sheet with a new $110 million credit facility and advances integration efforts targeting profitability in FY27.

Vectus Biosystems appoints Dr Tara Speranza as CEO and CTO to accelerate development of lead fibrosis drug VB0004 with performance-linked incentives.

Proteomics International Laboratories (ASX:PIQ) has denied any undisclosed material information following a sharp share price drop and heightened trading activity, pointing instead to recent strategic updates and organisational changes.

ARN Media reported a 10% revenue decline in FY25 but accelerated digital growth and cost savings, while defending ongoing legal disputes with former talent.

Arovella Therapeutics has named Dr Nicole Van Der Weerden as acting CEO following Dr Michael Baker’s departure, positioning her to steer the company through the critical phase I trial of its CAR-iNKT therapy ALA-101.